[go: up one dir, main page]

PE20141021A1 - DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO - Google Patents

DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO

Info

Publication number
PE20141021A1
PE20141021A1 PE2013002093A PE2013002093A PE20141021A1 PE 20141021 A1 PE20141021 A1 PE 20141021A1 PE 2013002093 A PE2013002093 A PE 2013002093A PE 2013002093 A PE2013002093 A PE 2013002093A PE 20141021 A1 PE20141021 A1 PE 20141021A1
Authority
PE
Peru
Prior art keywords
potassium channel
pyrimidine
inhibitors
derivatives
compound
Prior art date
Application number
PE2013002093A
Other languages
English (en)
Inventor
Derek Edward John
John Ford
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44071904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141021(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of PE20141021A1 publication Critical patent/PE20141021A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DE FORMULA (Ia), DONDE DICHO COMPUESTO COMPRENDE UNA MEZCLA DE LOS COMPUESTOS DE FORMULA (Ib) Y (Ic). REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES INHIBIDOR DEL CANAL DE POTASIO, SIENDO UTIL PARA EL TRATAMIENTO O PREVENCION DE LA ARRITMIA
PE2013002093A 2011-04-01 2012-03-29 DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO PE20141021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds

Publications (1)

Publication Number Publication Date
PE20141021A1 true PE20141021A1 (es) 2014-08-30

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002093A PE20141021A1 (es) 2011-04-01 2012-03-29 DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO

Country Status (43)

Country Link
US (1) US9249155B2 (es)
EP (1) EP2694518B1 (es)
JP (1) JP5826374B2 (es)
KR (1) KR20140023332A (es)
CN (1) CN103492392B (es)
AP (1) AP2013007198A0 (es)
AR (1) AR088735A1 (es)
AU (1) AU2012235882B2 (es)
BR (1) BR112013025236A2 (es)
CA (1) CA2831493A1 (es)
CL (1) CL2013002789A1 (es)
CO (1) CO6801756A2 (es)
CR (1) CR20130488A (es)
CU (1) CU24173B1 (es)
CY (1) CY1117025T1 (es)
DK (1) DK2694518T3 (es)
EA (1) EA201301111A1 (es)
EC (1) ECSP13012988A (es)
ES (1) ES2558563T3 (es)
GB (1) GB201105659D0 (es)
GT (1) GT201300225A (es)
HK (2) HK1193096A1 (es)
HR (1) HRP20151340T1 (es)
HU (1) HUE028438T2 (es)
IL (1) IL228555A0 (es)
MA (1) MA35064B1 (es)
ME (1) ME02314B (es)
MX (1) MX335937B (es)
NI (1) NI201300100A (es)
PE (1) PE20141021A1 (es)
PH (1) PH12013501952A1 (es)
PL (1) PL2694518T3 (es)
PT (1) PT2694518E (es)
RS (1) RS54458B1 (es)
RU (1) RU2013148627A (es)
SG (1) SG193578A1 (es)
SI (1) SI2694518T1 (es)
SM (1) SMT201500322B (es)
TN (1) TN2013000377A1 (es)
TW (1) TWI516265B (es)
UA (1) UA110131C2 (es)
WO (1) WO2012131379A1 (es)
ZA (1) ZA201307085B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922858A4 (en) * 2012-11-20 2016-06-15 Univ Mcgill THIENOPYRIMIDININHIBITORS OF FARNESYL AND / OR GERANYL GERANYL PYROPHOSPHATE SYNTHASE
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
SG11201911929XA (en) 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
CA2227384A1 (en) 1995-08-17 1997-02-27 Toshifumi Watanabe Thienopyrimidine derivatives, their production and use
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
SK7599A3 (en) 1996-07-26 1999-07-12 Nissan Chemical Ind Ltd Chroman derivatives and pharmaceutical composition containing the same
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク. カリウムチャネル阻害剤
WO2000012492A1 (en) 1998-09-01 2000-03-09 Nissan Chemical Industries, Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
AU766935B2 (en) 1999-09-17 2003-10-23 Nissan Chemical Industries Ltd. Benzopyran derivative
AU7319800A (en) 1999-09-24 2001-04-24 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
EP1218367A1 (en) 1999-10-05 2002-07-03 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1240147A1 (en) 1999-12-21 2002-09-18 Icagen, Inc. Potassium channel inhibitors
JP4854909B2 (ja) 2000-09-20 2012-01-18 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノン系カリウムチャンネル阻害剤
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
WO2002062343A2 (en) 2001-02-02 2002-08-15 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
IL159218A0 (en) 2001-06-25 2004-06-01 Nissan Chemical Ind Ltd Substituted benzopyran derivatives against arrhythmia
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
MXPA05013549A (es) * 2003-06-11 2006-04-05 Xention Discovery Ltd Derivados de tienopirimidina como inhibidores del canal de potasio.
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
CA2552598A1 (en) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
US7776867B2 (en) 2004-06-29 2010-08-17 Amgen Inc. Furanopyrimidines
EP1879899B1 (en) 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
KR20090021218A (ko) * 2006-06-12 2009-02-27 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서 유용한 티에노피리미딘
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Also Published As

Publication number Publication date
GB201105659D0 (en) 2011-05-18
CN103492392A (zh) 2014-01-01
MX2013011301A (es) 2014-04-16
CA2831493A1 (en) 2012-10-04
EP2694518B1 (en) 2015-10-07
TW201244720A (en) 2012-11-16
CU24173B1 (es) 2016-04-25
AP2013007198A0 (en) 2013-10-31
HK1193806A1 (zh) 2014-10-03
DK2694518T3 (en) 2015-11-09
AR088735A1 (es) 2014-07-02
EA201301111A1 (ru) 2014-02-28
CY1117025T1 (el) 2017-04-05
NI201300100A (es) 2014-01-07
SMT201500322B (it) 2016-02-25
JP2014509637A (ja) 2014-04-21
MX335937B (es) 2016-01-04
NZ615621A (en) 2015-01-30
GT201300225A (es) 2014-12-30
ECSP13012988A (es) 2013-12-31
CR20130488A (es) 2013-12-06
KR20140023332A (ko) 2014-02-26
RU2013148627A (ru) 2015-05-10
TN2013000377A1 (en) 2015-01-20
BR112013025236A2 (pt) 2019-09-24
MA35064B1 (fr) 2014-04-03
HUE028438T2 (en) 2017-02-28
UA110131C2 (ru) 2015-11-25
AU2012235882B2 (en) 2015-08-06
TWI516265B (zh) 2016-01-11
US20140206703A1 (en) 2014-07-24
JP5826374B2 (ja) 2015-12-02
RS54458B1 (en) 2016-06-30
CU20130124A7 (es) 2014-01-29
CL2013002789A1 (es) 2014-07-18
WO2012131379A1 (en) 2012-10-04
US9249155B2 (en) 2016-02-02
SG193578A1 (en) 2013-10-30
CO6801756A2 (es) 2013-11-29
PT2694518E (pt) 2016-02-05
SI2694518T1 (sl) 2016-02-29
IL228555A0 (en) 2013-12-31
EP2694518A1 (en) 2014-02-12
ES2558563T3 (es) 2016-02-05
HRP20151340T1 (hr) 2016-02-26
HK1193096A1 (zh) 2014-09-12
ME02314B (me) 2016-06-20
CN103492392B (zh) 2015-11-25
PL2694518T3 (pl) 2016-03-31
AU2012235882A1 (en) 2013-05-02
ZA201307085B (en) 2015-04-29
PH12013501952A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
NZ716840A (en) Combination formulation of two antiviral compounds
CA2875877C (en) Syk inhibitors
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
IN2014CN04530A (es)
PE20190973A1 (es) Compuestos de tetrahidropirazolopirimidina
UY32490A (es) Inhibidores de beta-secretasa
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
CR20120317A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
TW201613895A (en) Phosphatidylinositol 3-kinase inhibitors
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
UY33348A (es) Compuestos de furopiridina y usos de los mismos
MX2016004841A (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
EA201591649A1 (ru) Составы с органическими соединениями
PE20141021A1 (es) DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO
AR091402A1 (es) Profarmacos de acido fosforadimico

Legal Events

Date Code Title Description
FD Application declared void or lapsed